Functional characterization of novel germline TP53 variants in Swedish families

被引:10
|
作者
Kharaziha, Pedram [1 ]
Ceder, Sophia [1 ]
Axell, Olga [1 ]
Krall, Moritz [1 ]
Fotouhi, Omid [1 ]
Bohm, Stefanie [1 ]
Lain, Sonia [2 ]
Borg, Ake [3 ]
Larsson, Catharina [1 ]
Wiman, Klas G. [1 ]
Tham, Emma [4 ,5 ]
Bajalica-Lagercrantz, Svetlana [1 ,5 ]
机构
[1] Karolinska Univ Hosp, Karolinska Inst, Canc Ctr Karolinska, Dept Oncol Pathol, BioClinicum J6-20, SE-17176 Stockholm, Sweden
[2] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Stockholm, Sweden
[3] Lund Univ, Div Oncol Pathol, Lund, Sweden
[4] Karolinska Inst, Dept Mol Med & Surg, Stockholm, Sweden
[5] Karolinska Univ Hosp, Dept Clin Genet, Stockholm, Sweden
关键词
germline TP53 mutation; hereditary breast cancer; Li-Fraumeni syndrome; p53; activity; LI-FRAUMENI SYNDROME; ONSET BREAST-CANCER; MUTANT P53; MUTATION CARRIERS; IMAGING SURVEILLANCE; RISK; BINDING; BRCA2;
D O I
10.1111/cge.13564
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Pathogenic germline TP53 variants predispose to a wide range of early onset cancers, often recognized as the Li-Fraumeni syndrome (LFS). They are also identified in 1% of families with hereditary breast cancer (HrBC) that do not fulfill the criteria for LFS. In this study, we present a total of 24 different TP53 variants identified in 31 Swedish families with LFS or HrBC. Ten of these variants, nine exonic and one splice, have previously not been described as germline pathogenic variants. The nine exonic variants were functionally characterized and demonstrated partial transactivation activity compared to wild-type p53. Some show nuclear localization similar to wild-type p53 while others possess cytoplasmic or perinuclear localization. The four frameshift variants (W91Gfs*32, L111 Wfs*12, S227 Lfs*20 and S240Kfs*25) had negligible, while F134 L and T231del had low level of p53 activity. The L111 Wfs*12 and T231del variants are also deficient for induction of apoptosis. The missense variant R110C retain p53 effects and the nonsense E349* shows at least partial transcription factor activity but has reduced ability to trigger apoptosis. This is the first functional characterization of novel germline TP53 pathogenic or likely pathogenic variants in the Swedish cohort as an attempt to understand its association with LFS and HrBC, respectively.
引用
收藏
页码:216 / 225
页数:10
相关论文
共 50 条
  • [1] Germline TP53 Variants and Susceptibility to Osteosarcoma
    Mirabello, Lisa
    Yeager, Meredith
    Mai, Phuong L.
    Gastier-Foster, Julie M.
    Gorlick, Richard
    Khanna, Chand
    Patino-Garcia, Ana
    Sierrasesumaga, Luis
    Lecanda, Fernando
    Andrulis, Irene L.
    Wunder, Jay S.
    Gokgoz, Nalan
    Barkauskas, Donald A.
    Zhang, Xijun
    Vogt, Aurelie
    Jones, Kristine
    Boland, Joseph F.
    Chanock, Stephen J.
    Savage, Sharon A.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2015, 107 (07):
  • [2] Blood functional assay for rapid clinical interpretation of germline TP53 variants
    Raad, Sabine
    Rolain, Marion
    Coutant, Sophie
    Derambure, Celine
    Lanos, Raphael
    Charbonnier, Francoise
    Bou, Jacqueline
    Bouvignies, Emilie
    Lienard, Gwendoline
    Vasseur, Stephanie
    Farrell, Michael
    Ingster, Olivier
    Desurmont, Stephanie Baert
    Kasper, Edwige
    Bougeard, Gaelle
    Frebourg, Thierry
    Tournier, Isabelle
    JOURNAL OF MEDICAL GENETICS, 2021, 58 (12) : 796 - 805
  • [3] Rare germline TP53 variants in lung adenocarcinoma
    Parry, Erin Michelle
    Gable, Dustin L.
    Stanley, Susan E.
    Armanios, Mary Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [4] Characterization of germline TP53 splicing mutations and their genetic and functional analysis
    Varley, JM
    Attwooll, C
    White, G
    McGown, G
    Thorncroft, M
    Kelsey, AM
    Greaves, M
    Boyle, J
    Birch, JM
    ONCOGENE, 2001, 20 (21) : 2647 - 2654
  • [5] Characterization of germline TP53 splicing mutations and their genetic and functional analysis
    J M Varley
    C Attwooll
    G White
    G McGown
    M Thorncroft
    A M Kelsey
    M Greaves
    J Boyle
    J M Birch
    Oncogene, 2001, 20 : 2647 - 2654
  • [6] Functional evaluation of germline TP53 variants identified in Brazilian families at-risk for Li-Fraumeni syndrome
    Abreu, Renata B. V.
    Pereira, Ariane S.
    Rosa, Marcela N.
    Ashton-Prolla, Patricia
    Silva, Viviane A. O.
    Melendez, Matias E.
    Palmero, Edenir I.
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [7] Cancer risk in carriers of TP53 germline variants grouped into different functional categories
    Muentnich, Lucas John
    Dutzmann, Christina M.
    Grosshennig, Anika
    Haerter, Valentina
    Keymling, Myriam
    Mastronuzzi, Angela
    Montellier, Emilie
    Nees, Juliane
    Palmaers, Natalie E.
    Penkert, Judith
    Pfister, Stefan M.
    Ripperger, Tim
    Schott, Sarah
    Silchmueller, Farina
    Hainaut, Pierre
    Kratz, Christian P.
    JNCI CANCER SPECTRUM, 2025, 9 (01)
  • [8] Evaluation of TP53 Variants Detected on Peripheral Blood or Saliva Testing: Discerning Germline From Somatic TP53 Variants
    Schwartz, Alison N.
    Hyman, Sophie R.
    Stokes, Samantha M.
    Castillo, Danielle
    Tung, Nadine M.
    Weitzel, Jeffrey N.
    Rana, Huma Q.
    Garber, Judy E.
    JCO PRECISION ONCOLOGY, 2021, 5 : 1677 - 1686
  • [9] A NOVEL FUNCTIONAL CLASSIFICATION OF TP53 GERMLINE VARIANTS: CAN THIS INFORM CANCER SCREENING PRACTICES IN YOUNG CHILDREN?
    Freycon, Claire
    Montellier, Emilie
    Budd, Crystal
    Blanchet, Sandrine
    Tachdjian, Melissa
    Hainaut, Pierre
    Goudie, Catherine
    PEDIATRIC BLOOD & CANCER, 2023, 70 : S111 - S111
  • [10] Whole-body MRI within a surveillance program for carriers with clinically actionable germline TP53 variants - the Swedish constitutional TP53 study SWEP53
    Meis Omran
    Lennart Blomqvist
    Yvonne Brandberg
    Niklas Pal
    Per Kogner
    Anne Kinhult Ståhlbom
    Emma Tham
    Svetlana Bajalica-Lagercrantz
    Hereditary Cancer in Clinical Practice, 18